Literature DB >> 19050873

FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman's disease.

Rob Barker1, Fahrad Kazmi, Justin Stebbing, Sarah Ngan, Roger Chinn, Mark Nelson, Michael O'Doherty, Mark Bower.   

Abstract

PURPOSE: To evaluate the role of FDG-PET/CT scanning in the management of HIV-associated multicentric Castleman's disease (MCD) a rare lymphoproliferative disorder associated with infection by human herpesvirus 8 (HHV8).
MATERIALS AND METHODS: Nine patients with histologically confirmed MCD underwent fused FDG-PET/CT scans at initial MCD diagnosis (n = 3), at MCD relapse (n = 4), or during remission (n = 2). All seven patients with active MCD had markedly elevated plasma HHV8 viral loads, but the patients in remission had no HHV8 viraemia. The three patients with newly diagnosed MCD were not on antiretroviral therapy at the time of imaging, but the other six were all on fully suppressive antiretroviral regimens.
RESULTS: In the seven patients with active MCD (newly diagnosed or relapse) 33/91 lymph node groups (36%) included radiologically enlarged nodes on the CT scan, whilst 57/91 lymph node groups (63%) showed enhanced FDG uptake on the PET scan. In scans from patients in remission, there were no enlarged lymph nodes on the CT scan but 3 lymph nodes (11%) demonstrated enhanced FDG uptake. The median SUV recorded for the seven patients with active MCD was 4.8 (range 2.6-9.3) which was significantly higher than the median value of 2.5 recorded for the patients in remission (Mann-Whitney U test, p = 0.011).
CONCLUSION: Despite the small number of patients, in HIV-positive individuals with active MCD, FDG-PET scans more frequently detected abnormal uptake than CT scans detected enlarged lymph nodes. FDG-PET scanning has a useful role in the management of HIV-associated MCD in selecting appropriate sites for biopsy, and in staging and monitoring these lymphoproliferations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19050873     DOI: 10.1007/s00259-008-0998-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  18 in total

1.  FDG positron emission tomographic scintigraphy can reveal Castleman's disease as a cause of inflammation.

Authors:  D Blockmans; A Maes; S Stroobants; H Bobbaers; L Mortelmans
Journal:  Clin Nucl Med       Date:  2001-11       Impact factor: 7.794

2.  Nodal marginal zone B-cell lymphoma resembling plasmacytoma arising from a plasma cell variant of localized Castleman's disease: a case report.

Authors:  Masaru Kojima; Shigeo Nakamura; Kazuhiko Shimizu; Yoshio Suda; Yoshio Kasuga; Shiro Sugihara; Noriyuki Sakata; Nobuhide Masawa
Journal:  APMIS       Date:  2002-08       Impact factor: 3.205

3.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

Authors:  Martin Hutchings; Annika Loft; Mads Hansen; Lars Møller Pedersen; Thora Buhl; Jesper Jurlander; Simon Buus; Susanne Keiding; Francesco D'Amore; Anne-Marie Boesen; Anne Kiil Berthelsen; Lena Specht
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

4.  Unicentric and multicentric Castleman's disease.

Authors:  K Enomoto; I Nakamichi; K Hamada; A Inoue; I Higuchi; M Sekimoto; M Mizuki; Y Hoshida; T Kubo; K Aozasa; J Hatazawa
Journal:  Br J Radiol       Date:  2007-01       Impact factor: 3.039

5.  Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation.

Authors:  Douglas Brust; Michael Polis; Richard Davey; Barbara Hahn; Stephen Bacharach; Millie Whatley; Anthony S Fauci; Jorge A Carrasquillo
Journal:  AIDS       Date:  2006-04-24       Impact factor: 4.177

6.  FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

Authors:  N G Mikhaeel; M Hutchings; P A Fields; M J O'Doherty; A R Timothy
Journal:  Ann Oncol       Date:  2005-06-24       Impact factor: 32.976

7.  Follicular dendritic cell tumor and vascular neoplasm complicating hyaline-vascular Castleman's disease.

Authors:  J K Chan; W Y Tsang; C S Ng
Journal:  Am J Surg Pathol       Date:  1994-05       Impact factor: 6.394

8.  Imaging features of multicentric Castleman's disease in HIV infection.

Authors:  J C Hillier; P Shaw; R F Miller; J D Cartledge; M Nelson; M Bower; N Francis; S P Padley
Journal:  Clin Radiol       Date:  2004-07       Impact factor: 2.350

Review 9.  HIV-associated multicentric Castleman's disease.

Authors:  Justin Stebbing; Liron Pantanowitz; Farshid Dayyani; Ryan J Sullivan; Mark Bower; Bruce J Dezube
Journal:  Am J Hematol       Date:  2008-06       Impact factor: 10.047

10.  Brief communication: rituximab in HIV-associated multicentric Castleman disease.

Authors:  Mark Bower; Tom Powles; Sarah Williams; Tom Newsom Davis; Mark Atkins; Silvia Montoto; Chloe Orkin; Andy Webb; Martin Fisher; Mark Nelson; Brian Gazzard; Justin Stebbing; Peter Kelleher
Journal:  Ann Intern Med       Date:  2007-12-18       Impact factor: 25.391

View more
  18 in total

1.  18F-fluorodeoxyglucose positron emission tomography/computed tomography findings in a patient with human immunodeficiency virus-associated Castleman's disease and Kaposi sarcoma, disorders associated with human herpes virus 8 infection.

Authors:  Francesco Bertagna; Giorgio Biasiotto; Rosita Rodella; Raffaele Giubbini; Abass Alavi
Journal:  Jpn J Radiol       Date:  2010-05-01       Impact factor: 2.374

2.  FDG-PET imaging in the diagnosis of HIV-associated multicentric Castleman disease: something is still missing.

Authors:  Roberto Rossotti; Christina Moioli; Clara Schiantarelli; Carloandrea Orcese; Massimo Puoti
Journal:  Top Antivir Med       Date:  2012 Aug-Sep

3.  18F-fluorodeoxyglucose Positron Emission Tomography in Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease: Correlation With Activity, Severity, Inflammatory and Virologic Parameters.

Authors:  Mark N Polizzotto; Corina Millo; Thomas S Uldrick; Karen Aleman; Millie Whatley; Kathleen M Wyvill; Deirdre O'Mahony; Vickie Marshall; Denise Whitby; Roberto Maass-Moreno; Seth M Steinberg; Richard F Little; Robert Yarchoan
Journal:  J Infect Dis       Date:  2015-03-31       Impact factor: 5.226

4.  A retrospective study of 34 patients with unicentric and multicentric Castleman's disease: Experience from a single institution.

Authors:  Jin-Peng Jiang; Xiao-Fei Shen; Jun-Feng Du; Wen-Xian Guan
Journal:  Oncol Lett       Date:  2017-12-14       Impact factor: 2.967

5.  Castleman's disease arising from the gallbladder neck causing difficulty in the differential diagnosis.

Authors:  Kiminori Takano; Motohide Shimazu; Taizo Hibi; Yasushi Hasegawa; Masahiro Shinoda; Shigeyuki Kawachi; Minoru Tanabe; Koichi Aiura; Masakazu Ueda; Rie Irie; Yuko Kitagawa
Journal:  Clin J Gastroenterol       Date:  2010-01-19

Review 6.  HIV-associated multicentric Castleman disease.

Authors:  Deepa Reddy; Ronald Mitsuyasu
Journal:  Curr Opin Oncol       Date:  2011-09       Impact factor: 3.645

Review 7.  The Role of Nuclear Medicine in the Staging and Management of Human Immune Deficiency Virus Infection and Associated Diseases.

Authors:  Alfred O Ankrah; Andor W J M Glaudemans; Hans C Klein; Rudi A J O Dierckx; Mike Sathekge
Journal:  Nucl Med Mol Imaging       Date:  2016-05-25

8.  Anemia resolved by thoracoscopic resection of a mediastinal mass: a case report of unicentric Castleman's disease.

Authors:  Jong Hui Suh; Sook Hee Hong; Seong Cheol Jeong; Chan Beom Park; Kuk Bin Choi; Ok Ran Shin; Si Young Choi
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

9.  18F-FDG PET/CT imaging features of patients with multicentric Castleman disease.

Authors:  Yuanyuan Jiang; Guozhu Hou; Zhaohui Zhu; Li Huo; Fang Li; Wuying Cheng
Journal:  Nucl Med Commun       Date:  2021-07-01       Impact factor: 1.690

Review 10.  Emerging role of 18F-FDG PET/CT in Castleman disease: a review.

Authors:  Benjamin Koa; Austin J Borja; Mahmoud Aly; Sayuri Padmanabhan; Joseph Tran; Vincent Zhang; Chaitanya Rojulpote; Sheila K Pierson; Mark-Avery Tamakloe; Johnson S Khor; Thomas J Werner; David C Fajgenbaum; Abass Alavi; Mona-Elisabeth Revheim
Journal:  Insights Imaging       Date:  2021-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.